Company intelligence / Profile preview

Lazard US Systematic Small Cap Equity ETF

New York, New York, United Stateslazard.com ↗

Ownership: Public · SYZ
Employees: ~3000
Development stage: Other

Overview

Lazard is a leading global financial advisory and asset management firm. While it does not develop drugs or own clinical programs, it plays a prominent role in advising biopharmaceutical, biotechnology, and healthcare companies on mergers & acquisitions, capital markets transactions, strategic partnerships, and industry trends. Its annual Global Biopharmaceutical Leaders Study is widely cited for insights into sector priorities such as autoimmune diseases, oncology/solid tumors, rare diseases, neurology/CNS disorders, next-generation antibodies/antibody-drug conjugates/radiopharmaceuticals modalities.

Industry: Investors

Financials

Market cap: $67.7M
Enterprise value: $67.7M

Beyond the preview

Go deeper on Lazard US Systematic Small Cap Equity ETF.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lazard US Systematic Small Cap Equity ETF.

Explore the full profile